ALHC Stock Analysis: Alignment Healthcare | NASDAQ
Healthcare Plans | NASDAQ, USA | Market Cap: 4.920m USD | 12M Return: 48.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 121M
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alignment Healthcare, Inc. (NASDAQ: ALHC) operates a consumer-centric healthcare platform serving seniors in the United States. The company delivers customized healthcare experiences primarily through its Medicare Advantage plans.
Founded in 2013 and headquartered in Orange, California, Alignment Healthcare completed its IPO in March 2021 and is classified as a mid-cap stock within the Healthcare Services sub-industry. Medicare Advantage is a Medicare-managed care program offered by private insurers under contract with the federal government, serving as an alternative to traditional fee-for-service Medicare.
- Medicare Advantage membership growth drives premium revenue
- Medical loss ratio trends pressure health plan margins
- CMS reimbursement rate updates and Star ratings impact payments
| Net Income: 19.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 16.63 > 1.0 |
| NWC/Revenue: 11.50% < 20% (prev 10.57%; Δ 0.92% < -1%) |
| CFO/TA 0.20 > 3% & CFO 252.0m > Net Income 19.8m |
| Net Debt (-1.07b) to EBITDA (66.4m): -16.18 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (213.1m) vs 12m ago 10.08% < -2% |
| Gross Margin: 12.38% > 18% (prev 11.57%; Δ 0.81% > 0.5%) |
| Asset Turnover: 394.7% > 50% (prev 335.2%; Δ 59.50% > 0%) |
| Interest Coverage Ratio: 2.25 > 6 (EBIT TTM 35.7m / Interest Expense TTM 15.9m) |
| A: 0.39 (Total Current Assets 1.15b - Total Current Liabilities 656.0m) / Total Assets 1.26b |
| B: -0.79 (Retained Earnings -997.6m / Total Assets 1.26b) |
| C: 0.03 (EBIT TTM 35.7m / Avg Total Assets 1.08b) |
| D: 0.20 (Book Value of Equity 206.9m / Total Liabilities 1.05b) |
| Altman-Z'' = 0.40 = B |
| DSRI: 0.91 (Receivables 277.7m/214.1m, Revenue 4.26b/3.00b) |
| GMI: 0.93 (GM 11.57% / 12.38%) |
| AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.42 (Revenue 4.26b / 3.00b) |
| TATA: -0.18 (NI 19.8m - CFO 252.0m) / TA 1.26b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 19.83 with a total of 3,707,250 shares traded. Over the past week, the price has changed by -16.68%, over one month by -3.55%, over three months by -3.27% and over the past year by +48.21%.
Current recommended Stop Loss: 17.70 (which is 10.7% or 1.5 ATR below the current price).
Alignment Healthcare has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy ALHC.
- StrongBuy: 6
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 24.9 | 25.7% |
P/E Trailing = 238.0
P/E Forward = 204.0816
P/S = 1.1558
P/B = 23.7876
Revenue TTM = 4.26b USD
EBIT TTM = 35.7m USD
EBITDA TTM = 66.4m USD
Long Term Debt = 323.6m USD (from longTermDebt, last quarter)
Short Term Debt = 1.96m USD (from shortTermDebt, last fiscal year)
Debt = 336.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.35m
Net Debt = -1.07b USD (calculated: Debt 336.3m - CCE 1.41b)
Enterprise Value = 3.85b USD (4.92b + Debt 336.3m - CCE 1.41b)
Interest Coverage Ratio = 2.25 (Ebit TTM 35.7m / Interest Expense TTM 15.9m)
EV/FCF = 16.25x (Enterprise Value 3.85b / FCF TTM 236.6m)
FCF Yield = 6.15% (FCF TTM 236.6m / Enterprise Value 3.85b)
FCF Margin = 5.56% (FCF TTM 236.6m / Revenue TTM 4.26b)
Net Margin = 0.47% (Net Income TTM 19.8m / Revenue TTM 4.26b)
Gross Margin = 12.38% ((Revenue TTM 4.26b - Cost of Revenue TTM 3.73b) / Revenue TTM)
Gross Margin QoQ = 11.70% (prev 12.18%)
Tobins Q-Ratio = 3.05 (Enterprise Value 3.85b / Total Assets 1.26b)
Interest Expense / Debt = 4.73% (Interest Expense 15.9m / Debt 336.3m)
Taxrate = 0.12% (24.0k / 19.8m)
NOPAT = 35.7m (EBIT 35.7m * (1 - 0.12%))
Current Ratio = 1.75 (Total Current Assets 1.15b / Total Current Liabilities 656.0m)
Debt / Equity = 1.63 (Debt 336.3m / totalStockholderEquity, last quarter 206.9m)
Debt / EBITDA = -16.18 (Net Debt -1.07b / EBITDA 66.4m)
Debt / FCF = -4.54 (Net Debt -1.07b / FCF TTM 236.6m)
Total Stockholder Equity = 172.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.84% (Net Income 19.8m / Total Assets 1.26b)
RoE = 11.50% (Net Income TTM 19.8m / Total Stockholder Equity 172.2m)
RoCE = 7.20% (EBIT 35.7m / Capital Employed (Equity 172.2m + L.T.Debt 323.6m))
RoIC = 9.04% (NOPAT 35.7m / Invested Capital 394.7m)
WACC = 4.75% (E(4.92b)/V(5.26b) * Re(4.75%) + D(336.3m)/V(5.26b) * Rd(4.73%) * (1-Tc(0.00)))
Discount Rate = 4.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 5.65%
[DCF] Terminal Value 77.97% ; FCFF base≈149.6m ; Y1≈171.5m ; Y5≈252.4m
[DCF] Fair Price = 23.57 (EV 3.80b - Net Debt -1.07b = Equity 4.87b / Shares 206.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.50 | # QB: 0
Revenue Correlation: 99.84 | Revenue CAGR: 44.70% | SUE: 1.13 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=+0.00% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.14 | Chg30d=+0.00% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.47 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+47.8% | GrowthRev=+31.4%
EPS next Year (2027-12-31): EPS=0.72 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+52.1% | GrowthRev=+25.5%
[Analyst] Revisions Ratio: +10% (up=4, down=3)